Frequently asked questions about us
Q: What does the company do?
A: Frelii Inc. is a biotech company, that has developed an Artificial Intelligence (AI) for use with DNA sequencing. Its technology has been designed to allow assessment and sequencing, for reporting needs into various life science environments.
A: Frelii is essentially data mining DNA. The company leverages the big data of DNA to improve health and wellness and enhance the human experience. Frelii uses its unique technology to take a fundamentally different approach than what others in the market are doing. It leverages its AI to interpret DNA testing results, delivering much greater insight and decision making perspective than what is currently available. Frelii enables visualization into epigenetic expression as clusters of millions of 3D models. Through this, its AI derives meaning from the clusters with true interconnected data. As such, Frelii opens the door to far more specific and accurate DNA analysis and far broader applications to a number of market segments.
Q: Where is the company headquartered?
A: Lehi, Utah
Q: Is it a public company?
A: Yes, Frélii is traded on the OTCQB exchange under the ticker symbol: FRLI
Q: What makes it unique?
A: Frélii takes a unique approach to health by leveraging its highly advanced AI to deliver more holistic DNA analysis to provide precision regarding what medical professionals and individuals need regarding correct drugs, dosing, diet and interventions. Using whole-genome analysis with artificial intelligence bridges the gap between genetics and epigenetics, giving real actionable information to provide medical professionals with better information to make better choices.
Q: What are the key differentiators of your solutions and services?
A: Frélii continues to develop and grow its patented AI technology, leveraged base code and large data sets gathered from public and private partnerships. Frélii’s predictive capacity with its precision medicine and health and wellness AI has increased from 84% to 98.5%. And the flagship high-efficiency Genetic Sequencing and analysis using Frélii’s proprietary technology has increased to greater than 99% and 99.999% accuracy on whole genome and exome sequencing, respectively.
A: To bring this into perspective, current competitive solutions analyze about 400,000 data points, generating approximately 384 outcomes, such as diet suggestions or identification of potential health risks. The Frélii AI technology has dramatically increased the data points analyzed to more than 60 million, yielding more than 60 million outcomes. This represents a paradigm-changing jump in the availability of accurate, whole genome sequencing and analysis.
Q: What problem does it solve?
A: The current industry challenge is medical science is generalizing what populations need, not individual patients. For instance, current drug studies propose a certain drug that should work for 80% of the people, but in the meantime, it might kill 3% of study participants. Such risks are unacceptable given current technology. Society is jeopardizing people’s lives because we have not had the capability to be precise. Instead of guessing and risking death from adverse reactions, whole genome analysis provides precision and assurance.
A: In regards to legal medical cannabis, this rapid-growth market is facing some serious challenges. Patients do not know how to use it appropriately and medical professionals do not know how to correctly recommend, prescribe or dose it. The reality is it can be an incredible intervention if done correctly. People who should be using it and benefiting from it are not because 1. Lack of information regarding how it will affect them, 2. Slight health risks including psychosis and others. Frélii is partnering with medical organizations to enable medical professionals to apply DNA analysis (patients and plants) that will enable doctors to improve their prescriptive methodologies.
Q: How big is the market opportunity?
A: The underlying technology that Frélii has developed can impact the multi-trillion dollar health, wellness and insurance markets.
Q: What markets does Frelii target?
A: Medical Cannabis. In geographies where medical cannabis is legal, such as Canada, the application of Frélii’s AI can be used to help medical professionals determine the best or most appropriate plant genetics and dose to use with patients based on the patient's genetic information. In addition to having human DNA sequencing reporting, Frelii has also created a database that will work dynamically with the DNA reporting of approximately 90,000 cannabis strains. This will allow cancer and pain management industries to perfectly align specific cannabis strains to patient diagnosis and treatment strategies. The Frélii technology has the potential to greatly impact how medical cannabis is used for medicinal purposes making treatment safer, kinder and faster. This will first be in non-US countries where it is legal until fully federally legal with medical marijuana in the US.
A: Telemedicine. Physicians and labs will order DNA sequencing on patients, to align everything from supplements, to medical marijuana, to pharma, based on how our company’s DNA report aligns. This will first be non-US, until fully federally legal with medical marijuana in US.
A: Precision Medicine. Physicians, labs pharmaceutical companies and healthcare institutions will use our DNA sequencing reports for patient treatment alignment. Because Frélii conducts whole-genosequencing, its technology can be leveraged to advance precision medicine when used for disease treatment and prevention by taking into consideration an individual patient's complete genome with more than 60 million data points, providing 68 million outcomes. Medical professionals and researchers will be able to more accurately predict and provide treatment strategies. In regards to telehealth, physicians and labs will order DNA sequencing on patients to align everything from supplements, to medical marijuana, to pharmaceuticals, based on how the Frélii DNA report aligns.
A: Life and Health Insurance. Frelii helps people from having to pay for the mistakes of their parents and grandparents with the use DNA data for true, real-time understanding of health and longevity. Saving the insurer and the insured money. Life and health insurance companies and corporate healthcare would Frelii DNA reports to assess coverage likelihood and coverage types, inclusions or exclusions. The Company believes that this application of its technology may provide far more accurate underwriting than simple blood tests and physical exams, which is the current method of information gathering for life insurance providers.
A: Consumer Wellness. Frélii empowers consumers to use their DNA to better understand their unique nutrition and health needs and receive meal plans and supplement recommendations that specifically align to their individual needs and risk factors. Frélii has plans in the near future to offer corporate wellness organizations the opportunity to enhance their personalized wellness plans by ordering lab diagnostic kits for more comprehensive blood testing and analysis.
A: Hospital Systems. The Company's technology and its application to diagnostic, health risk identification and precision medicine could improve health care and lower costs of health providers. Health providers will use the Company's technology to identify risks before symptoms or complaints arise, when such health issues could be addressed more efficiently and potentially more cost-effectively.
Q: Why does the company have high growth potential?
A: Frelii has cutting edge technology and implementation as well as high-growth channel partners including medical networks medical organizations
Q: Who are the key team members?
A: Chief Executive Officer, Ian Jenkins has more than 10 years of experience as a senior executive in the health and wellness industry, and an extensive background in physiology, technology startups, and supplement product research and development.
A: Director James Spallino has over 35 years of experience in the integrative medical and dental industry as both an entrepreneur and consultant.
A: Director and Chief Medical Officer, Dr. Hans Jenkins is a board-certified physician specializing in preventive health education, medical screenings, and lifestyle modifications to obtain optimal health.
A: Chief Technology Officer and Director, Jayson Uffens is a senior technology architect with more than two decades of executive experience at high-growth technology firms like GrubHub, Northrop Grumman, and GoDaddy.
A: Director Tarek Mango has been involved in international trade and business development for over 20 years, and has successfully consulted for, built, and introduced U.S. health care-related brands into Middle Eastern, Asian, and European markets.
A: Director, Leslie Norris has nearly 40 years of experience as business strategist, investor and brand expert and has worked with Fortune 100, mid-cap, early stage and startups, all in a global capacity. She has founded and served as CEO of advertising and PR agencies as well as a risk and regulatory compliance firm. In addition, she serves as an independent consultant and advisor to tech and life science companies, providing insight for business planning, executive leadership, operational efficiency, strategic planning and global emergence.
A: Chief Marketing Officer, Seth Jones is a marketing strategist and digital media expert, produced and distributed digital content that generated more than 4.5 million subscribers and over 915 million views on YouTube and over 3.2 million subscribers and over a billion views on Facebook for an extreme sports and adventure video production company.
Q: What makes the team uniquely capable?
A: Frelii has found exceptionally bright and creative people who are on the cutting edge of science and technology.
Q: What are the company’s products?
- Artificial Intelligence and DNA analysis: Navii
- Mental health analysis and artificial intelligence
- Telehealth products with partners
- DNA analysis for insurance and underwriting
- Pharmaco Analysis
- Health and Wellness
- Research AI
- Production AI